Nextcure Inc Quick Ratio (NXTC) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Nextcure Inc   (NASDAQ: NXTC)

Nextcure Inc 's Quick Ratio

NXTC's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Nextcure Inc 's Cash & cash equivalent grew by 32.45 % in the Q2 2026 sequentially, while Current Liabilities decreased, this led to improvement in Nextcure Inc 's Quick Ratio to 3.13, Quick Ratio remained below Nextcure Inc average.

Within Major Pharmaceutical Preparations industry 230 other companies have achieved higher Quick Ratio than Nextcure Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 1351, from total ranking in the first quarter 2026 at 1520.

Explain Quick Ratio?
How much Cash & cash equivalents NXTC´s has?
What are NXTC´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NXTC Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change -40.52 % 20.05 % 10.36 % 26.79 % -0.48 %
Y / Y Cash & cash equivalent Change 310.63 % -30.51 % -6.29 % -73.56 % -76.53 %
Quick Ratio MRQ 3.13 2.2 2.46 0.67 0.45
NXTC's Total Ranking # 1351 # 1520 # 2725 # 3241 # 1083
Seq. Current Liabilities Change -6.94 % -34.78 % -3.9 % 1.98 % 87.82 %
Seq. Cash & cash equivalent Change 32.45 % -41.62 % 254.75 % 49.71 % -77.59 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 231
Healthcare Sector # 394
Overall Market # 1081


Quick Ratio Statistics
High Average Low
50.72 13.13 0.45
(Sep 30 2020)   (Jun 30 2025)




Financial Statements
Nextcure Inc 's Current Liabilities $ 6 Millions Visit NXTC's Balance sheet
Nextcure Inc 's Cash & cash equivalent $ 20 Millions Visit NXTC's Balance sheet
Source of NXTC's Sales Visit NXTC's Sales by Geography


Cumulative Nextcure Inc 's Quick Ratio

NXTC's Quick Ratio for the trailling 12 Months

NXTC Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 0.28 % 12.68 % -1.5 % 3.11 % 2.71 %
Y / Y Cash & cash equivalent TTM Growth -16.54 % -45.6 % -36.57 % -22.78 % 14.4 %
Quick Ratio TTM 1.97 1.36 1.58 1.67 2.36
Total Ranking TTM # 1032 # 1044 # 727 # 531 # 440
Seq. Current Liabilities TTM Growth -11.13 % 3.02 % 2.67 % 6.68 % -0.15 %
Seq. Cash & cash equivalent TTM Growth 28.48 % -11.1 % -2.82 % -24.81 % -16.26 %

Quick ratio ranking by company, industry and sector >> Back to NXTC Financial Strength Comparisons >> Go to Compare NXTC Quick Ratio to its Competitors

On the trailing twelve months basis NXTC Cash & cash equivalent more than doubled by 310.63 % in Q2 2026 year on year, while Current Liabilities decreased to $6 millions, this led to increase in in Nextcure Inc 's Quick Ratio to 1.97, Quick Ratio remained below NXTC average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 432 other companies have achieved higher Quick Ratio than Nextcure Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 2920.

Explain Quick Ratio?
How much Cash & cash equivalents NXTC´s has?
What are NXTC´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 433
Healthcare Sector # 884
Within the Market # 1351


trailing twelve months Quick Ratio Statistics
High Average Low
7.32 3.17 1.36
(Dec 31 2019)   (Mar 31 2026)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Medicinova Inc   8.58 $ 25.416  Millions$ 2.961  Millions
Lixte Biotechnology Holdings Inc   8.45 $ 12.670  Millions$ 1.500  Millions
Atrium Therapeutics Inc   8.38 $ 264.135  Millions$ 31.508  Millions
Cytomx Therapeutics Inc   8.29 $ 330.280  Millions$ 39.861  Millions
Grace Therapeutics Inc  8.24 $ 13.756  Millions$ 1.669  Millions
Talphera Inc   7.98 $ 33.410  Millions$ 4.188  Millions
Rocket Pharmaceuticals Inc   7.79 $ 342.940  Millions$ 44.031  Millions
Milestone Pharmaceuticals Inc   7.73 $ 171.481  Millions$ 22.184  Millions
Nuvation Bio Inc   7.62 $ 660.956  Millions$ 86.755  Millions
Ibio inc   7.50 $ 88.049  Millions$ 11.745  Millions
Promis Neurosciences inc   7.41 $ 53.463  Millions$ 7.218  Millions
Lakewood-Amedex Biotherapeutics Inc.  7.29 $ 4.585  Millions$ 0.629  Millions
Aspire Biopharma Holdings Inc   7.22 $ 12.167  Millions$ 1.686  Millions
Cartesian Therapeutics Inc   7.18 $ 147.606  Millions$ 20.550  Millions
Kiora Pharmaceuticals Inc   7.10 $ 16.839  Millions$ 2.370  Millions
Arvinas Inc   6.88 $ 567.900  Millions$ 82.500  Millions
Summit Therapeutics Inc   6.67 $ 690.749  Millions$ 103.566  Millions
Alumis inc   6.59 $ 502.300  Millions$ 76.233  Millions
Novelos Therapeutics, Inc.  6.49 $ 33.994  Millions$ 5.238  Millions
Genprex Inc   6.47 $ 15.154  Millions$ 2.342  Millions
Lisata Therapeutics Inc   6.45 $ 19.277  Millions$ 2.987  Millions
Larimar Therapeutics Inc   6.44 $ 219.880  Millions$ 34.166  Millions
United Therapeutics Corporation  6.13 $ 3,724.700  Millions$ 607.800  Millions
Serina Therapeutics Inc   6.12 $ 23.024  Millions$ 3.762  Millions
Revelation Biosciences Inc   6.11 $ 11.483  Millions$ 1.880  Millions
Spero Therapeutics Inc   6.02 $ 50.774  Millions$ 8.428  Millions
Aquestive Therapeutics Inc   5.98 $ 98.490  Millions$ 16.478  Millions
Xencor Inc  5.94 $ 486.350  Millions$ 81.865  Millions
Zymeworks Inc   5.73 $ 270.699  Millions$ 47.243  Millions
Tonix Pharmaceuticals Holding Corp   5.72 $ 176.232  Millions$ 30.785  Millions

Date modified: 2026-09-08T04:25:33+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.